Treatment  	Treatment  	 NN	O
of  	of  	 IN	O
rheumatoid  	rheumatoid  	 JJ	B-NP
arthritis  	arthritis  	 NN	I-NP
and  	and  	 CC	O
ankylosing  	ankylosing  	 NNS	B-NP
spondylitis  	spondylitis  	 VBP	O
The  	The  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
most  	most  	 RBS	O
frequent  	frequent  	 JJ	O
inflammatory  	inflammatory  	 FW	B-NP
rheumatic  	rheumatic  	 FW	I-NP
diseases  	diseases  	 FW	I-NP
rheumatoid  	rheumatoid  	 FW	I-NP
arthritis  	arthritis  	 FW	I-NP
( 	( 	 -LRB-	O
RA 	RA 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
ankylosing  	ankylosing  	 JJ	B-NP
spondylitis  	spondylitis  	 NNS	I-NP
( 	( 	 -LRB-	O
AS 	AS 	 NNP	B-NP
)  	)  	 -RRB-	O
has  	has  	 VBZ	O
some  	some  	 DT	O
similarities  	similarities  	 NNS	B-NP
but  	but  	 CC	O
in  	in  	 IN	O
total  	total  	 JJ	O
more  	more  	 JJR	O
differences 	differences 	 NNS	O
.  	.  	 .	O
Thus 	Thus 	 RB	O
,  	,  	 ,	O
therapy  	therapy  	 NN	O
with  	with  	 IN	O
non-steroidal  	non-steroidal  	 JJ	B-NP
anti-inflammatory  	anti-inflammatory  	 JJ	I-NP
agents  	agents  	 NNS	I-NP
( 	( 	 -LRB-	O
NSAIDs 	NSAIDs 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
conventional  	conventional  	 JJ	B-NP
disease  	disease  	 NN	I-NP
modifying  	modifying  	 VBZ	I-NP
anti-rheumatic  	anti-rheumatic  	 JJ	I-NP
drugs  	drugs  	 NNS	I-NP
( 	( 	 -LRB-	O
DMARDs 	DMARDs 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
biologic  	biologic  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
has  	has  	 VBZ	O
a  	a  	 DT	O
different  	different  	 JJ	O
role  	role  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
management  	management  	 NN	O
and  	and  	 CC	O
different  	different  	 JJ	O
efficacy  	efficacy  	 NN	O
in  	in  	 IN	O
AS  	AS  	 NNP	O
and  	and  	 CC	O
RA 	RA 	 NNP	B-NP
.  	.  	 .	O
This  	This  	 DT	O
implies  	implies  	 JJ	O
signs  	signs  	 NNS	O
and  	and  	 CC	O
symptoms 	symptoms 	 NNS	B-NP
,  	,  	 ,	O
function 	function 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
structural  	structural  	 JJ	B-NP
damage 	damage 	 NN	I-NP
.  	.  	 .	O
This  	This  	 DT	O
is  	is  	 VBZ	O
in  	in  	 IN	O
part  	part  	 NN	O
due  	due  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
different  	different  	 JJ	O
pathogenesis 	pathogenesis 	 NN	B-NP
:  	:  	 :	O
( 	( 	 -LRB-	O
i 	i 	 FW	O
)  	)  	 -RRB-	O
while  	while  	 IN	O
the  	the  	 DT	O
synovium  	synovium  	 NN	B-NP
is  	is  	 VBZ	O
an  	an  	 DT	O
important  	important  	 JJ	O
target  	target  	 NN	O
in  	in  	 IN	O
RA  	RA  	 NNP	B-NP
it  	it  	 PRP	O
is  	is  	 VBZ	O
rather  	rather  	 RB	O
the  	the  	 DT	O
bone  	bone  	 NN	O
in  	in  	 IN	O
AS  	AS  	 NNP	O
and  	and  	 CC	O
( 	( 	 -LRB-	O
ii 	ii 	 LS	O
)  	)  	 -RRB-	O
while  	while  	 IN	O
the  	the  	 DT	O
pathology  	pathology  	 NN	B-NP
in  	in  	 IN	O
RA  	RA  	 NNP	B-NP
is  	is  	 VBZ	O
rather  	rather  	 RB	O
osteodestructive  	osteodestructive  	 VBN	O
to  	to  	 TO	O
cartilage  	cartilage  	 VB	O
and  	and  	 CC	O
bone  	bone  	 NN	O
presenting  	presenting  	 NN	O
with  	with  	 IN	O
erosions 	erosions 	 NN	O
,  	,  	 ,	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
predominantly  	predominantly  	 RB	O
osteoproliferative  	osteoproliferative  	 VBN	O
in  	in  	 IN	O
AS  	AS  	 NNP	O
as  	as  	 RB	O
indicated  	indicated  	 VBN	O
by  	by  	 IN	O
syndesmophytes  	syndesmophytes  	 NN	B-NP
and  	and  	 CC	O
ankylosis 	ankylosis 	 NN	B-NP
.  	.  	 .	O
Biologic  	Biologic  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
targeting  	targeting  	 VBG	I-NP
tumor  	tumor  	 NN	I-NP
necrosis  	necrosis  	 NN	I-NP
factor  	factor  	 NN	I-NP
( 	( 	 -LRB-	O
TNF-alpha 	TNF-alpha 	 NNP	B-NP
)  	)  	 -RRB-	O
work  	work  	 VBP	O
clinically  	clinically  	 RB	O
well  	well  	 RB	O
in  	in  	 IN	O
both  	both  	 DT	O
diseases  	diseases  	 NNS	O
but 	but 	 CC	O
,  	,  	 ,	O
while  	while  	 IN	O
they  	they  	 PRP	O
clearly  	clearly  	 RB	O
inhibit  	inhibit  	 VB	O
structural  	structural  	 JJ	B-NP
damage  	damage  	 NN	I-NP
in  	in  	 IN	O
RA 	RA 	 NNP	B-NP
,  	,  	 ,	O
they  	they  	 PRP	O
do  	do  	 VBP	O
not  	not  	 RB	O
seem  	seem  	 VB	O
to  	to  	 TO	O
have  	have  	 VB	O
much  	much  	 JJ	O
influence  	influence  	 NN	O
on  	on  	 IN	O
new  	new  	 JJ	O
bone  	bone  	 NN	O
formation  	formation  	 NN	O
in  	in  	 IN	O
AS 	AS 	 NNP	O
.  	.  	 .	O
DMARDs  	DMARDs  	 NNS	B-NP
are  	are  	 VBP	O
efficacious  	efficacious  	 VBN	O
in  	in  	 IN	O
RA  	RA  	 NNP	B-NP
but  	but  	 CC	O
less  	less  	 RBR	O
so  	so  	 RB	O
in  	in  	 IN	O
AS 	AS 	 NNP	O
.  	.  	 .	O
NSAIDs  	NSAIDs  	 NNS	B-NP
are  	are  	 VBP	O
efficacious  	efficacious  	 VBN	O
in  	in  	 IN	O
both  	both  	 DT	O
RA  	RA  	 NNP	B-NP
and  	and  	 CC	O
AS 	AS 	 NNP	O
,  	,  	 ,	O
but  	but  	 CC	O
they  	they  	 PRP	O
are  	are  	 VBP	O
considered  	considered  	 VBN	O
first  	first  	 JJ	O
line  	line  	 NN	O
of  	of  	 IN	O
therapy  	therapy  	 NN	O
in  	in  	 IN	O
AS  	AS  	 NNP	O
while  	while  	 IN	O
they  	they  	 PRP	O
are  	are  	 VBP	O
rather  	rather  	 RB	O
adjunctive  	adjunctive  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
in  	in  	 IN	O
RA 	RA 	 NNP	B-NP
.  	.  	 .	O
In  	In  	 IN	O
AS 	AS 	 NNP	O
,  	,  	 ,	O
NSAIDs 	NSAIDs 	 NNP	B-NP
,  	,  	 ,	O
potentially  	potentially  	 RB	O
especially  	especially  	 RB	O
coxibs 	coxibs 	 JJ	O
,  	,  	 ,	O
may  	may  	 MD	O
even  	even  	 RB	O
prevent  	prevent  	 VB	O
new  	new  	 JJ	O
bone  	bone  	 NN	O
formation  	formation  	 NN	O
due  	due  	 JJ	O
to  	to  	 TO	O
their  	their  	 PRP$	O
inhibitory  	inhibitory  	 JJ	B-NP
effect  	effect  	 NN	I-NP
on  	on  	 IN	O
cyclooxygenase-2 	cyclooxygenase-2 	 CD	B-NP
.  	.  	 .	O
